Dyloject patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946292 JAVELIN PHARMS INC Formulations of low dose diclofenac and beta-cyclodextrin
Mar, 2027

(3 years from now)

Dyloject is owned by Javelin Pharms Inc.

Dyloject contains Diclofenac Sodium.

Dyloject has a total of 1 drug patent out of which 0 drug patents have expired.

Dyloject was authorised for market use on 23 December, 2014.

Dyloject is available in solution;intravenous dosage forms.

Dyloject can be used as management of pain.

The generics of Dyloject are possible to be released after 22 March, 2027.

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 23 December, 2014

Treatment: Management of pain


How can I launch a generic of DYLOJECT before it's drug patent expiration?
More Information on Dosage

DYLOJECT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic